Targeting Mechanisms of Protein Degradation for Cancer Therapy—Volume II
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 6 January 2025 | Viewed by 339
Special Issue Editor
Interests: autophagy; NEDD8-mediated protein turnover; experimental therapeutics; drug discovery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the second edition of the Special Issue Targeting Mechanisms of Protein Degradation for Cancer Therapy
Timed protein degradation is an essential component of maintaining cellular homeostasis; however, this process frequently becomes dysregulated during oncogenesis and malignant progression. Aberrant protein turnover contributes to poor outcomes and drug resistance in a number of forms of cancer. The disrupted protein homeostasis in malignant cells creates an opportunity for selective, targeted therapeutic approaches based on the specific alterations in the protein degradation machinery that affect individual tumor types. The proof of concept that antagonizing dysregulated protein turnover yields anti-cancer benefits was first demonstrated with the proteasome inhibitor bortezomib, which became the first drug with this specific mechanism of action to ultimately earn FDA approval. The success of bortezomib prompted the development of second-generation proteasome inhibitors, as well as many other new agents that more specifically target key regulators of protein turnover. This Special Issue will focus on current approaches to selectively target mechanisms of protein degradation for cancer therapy.
Dr. Jennifer S. Carew
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- protein degradation
- proteasome inhibitor
- cancer therapy
- anti-cancer
- mechanisms
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
